Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer

doi:10.1016/j.apradiso.2017.05.006

Title: Automated cassette-based production of high specific activity [ ^203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer

Abstract

A method for preparation of Pb-212 and Pb-203 labeled chelator-modified peptide-based radiopharmaceuticals for cancer imaging and radionuclide therapy has been developed and adapted for automated clinical production. Pre-concentration and isolation of radioactive Pb2+ from interfering metals in dilute hydrochloric acid was optimized using a commercially-available Pb-specific chromatography resin packed in disposable plastic columns. The pre-concentrated radioactive Pb2+ is eluted in NaOAc buffer directly to the reaction vessel containing chelator-modified peptides. Radiolabeling was found to proceed efficiently at 85 °C (45 min; pH 5.5). The specific activity of radiolabeled conjugates was optimized by separation of radiolabeled conjugates from unlabeled peptide via HPLC. Preservation of bioactivity was confirmed by in vivo biodistribution of Pb-203 and Pb-212 labeled peptides in melanoma-tumor-bearing mice. The approach has been found to be robustly adaptable to automation and a cassette-based fluid-handling system (Modular Lab Pharm Tracer) has been customized for clinical radiopharmaceutical production. Our findings demonstrate that the Pb-203/Pb-212 combination is a promising elementally-matched radionuclide pair for image-guided radionuclide therapy for melanoma, neuroendocrine tumors, and potentially other cancers.

Authors:

Li, Mengshi ^[1]; Zhang, Xiuli ^[2]; Quinn, Thomas P. ^[2]; Lee, Dongyoul ^[1]; Liu, Dijie ^[3]; Kunkel, Falk ^[4]; Zimmerman, Brian E. ^[5]; McAlister, Daniel ^[6]; Olewein, Keith ^[7]; Menda, Yusuf ^[8];

^[9];

^[9]; Johnson, Frances L. ^[10]; Schultz, Michael K. ^[11]

Univ. of Iowa, Iowa City, IA (United States). Interdisciplinary Graduate Program in Human Toxicology
Univ. of Missouri, Columbia, MO (United States). Dept. of Biochemistry
Univ. of Iowa, Iowa City, IA (United States). Stead Family Dept. of Pediatrics
Eckert & Ziegler Radiopharma GmbH, Berlin (Germany)
National Inst. of Standards and Technology (NIST), Gaithersburg, MD (United States)
Eichrom Technologies, LLC, Lisle, IL (United States)
Lantheus Medical Imaging North Billerica, MA (United States)
Univ. of Iowa, Iowa City, IA (United States). Dept. of Radiology
Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
Viewpoint Molecular Targeting, LLC, Coralville, IA (United States); Univ. of Iowa, Iowa City, IA (United States). Carver College of Medicine, Dept. of Internal Medicine
Univ. of Iowa, Iowa City, IA (United States). Interdisciplinary Graduate Program in Human Toxicology; Univ. of Iowa, Iowa City, IA (United States). Stead Family Dept. of Pediatrics; Univ. of Iowa, Iowa City, IA (United States). Dept. of Radiology; Viewpoint Molecular Targeting, LLC, Coralville, IA (United States); Univ. of Iowa, Iowa City, IA (United States). Carver College of Medicine, Dept. of Radiation Oncology; Univ. of Iowa, Iowa City, IA (United States). Dept. of Chemistry

Publication Date:: 2017-05-10

Research Org.:: Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)

Sponsoring Org.:: USDOE

OSTI Identifier:: 1491308

Grant/Contract Number:: AC05-00OR22725

Resource Type:: Accepted Manuscript

Journal Name:: Applied Radiation and Isotopes

Additional Journal Information:: Journal Volume: 127; Journal Issue: C; Journal ID: ISSN 0969-8043

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Subject:: 59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES; Radionuclides; Pb-203; Pb-212; Alpha particle therapy; Peptides; Radiopharmaceuticals

Citation Formats


                    Li, Mengshi, Zhang, Xiuli, Quinn, Thomas P., Lee, Dongyoul, Liu, Dijie, Kunkel, Falk, Zimmerman, Brian E., McAlister, Daniel, Olewein, Keith, Menda, Yusuf, Mirzadeh, Saed, Copping, Roy, Johnson, Frances L., and Schultz, Michael K. Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.  United States: N. p., 2017. 
        Web.  doi:10.1016/j.apradiso.2017.05.006.

Copy to clipboard


                    Li, Mengshi, Zhang, Xiuli, Quinn, Thomas P., Lee, Dongyoul, Liu, Dijie, Kunkel, Falk, Zimmerman, Brian E., McAlister, Daniel, Olewein, Keith, Menda, Yusuf, Mirzadeh, Saed, Copping, Roy, Johnson, Frances L., & Schultz, Michael K. Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.  United States.  doi:10.1016/j.apradiso.2017.05.006.

Copy to clipboard


                    Li, Mengshi, Zhang, Xiuli, Quinn, Thomas P., Lee, Dongyoul, Liu, Dijie, Kunkel, Falk, Zimmerman, Brian E., McAlister, Daniel, Olewein, Keith, Menda, Yusuf, Mirzadeh, Saed, Copping, Roy, Johnson, Frances L., and Schultz, Michael K. Wed .  
        "Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer".  United States.  doi:10.1016/j.apradiso.2017.05.006.  https://www.osti.gov/servlets/purl/1491308.

Copy to clipboard


                    
@article{osti_1491308,

  title        = {Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer},

  author       = {Li, Mengshi and Zhang, Xiuli and Quinn, Thomas P. and Lee, Dongyoul and Liu, Dijie and Kunkel, Falk and Zimmerman, Brian E. and McAlister, Daniel and Olewein, Keith and Menda, Yusuf and Mirzadeh, Saed and Copping, Roy and Johnson, Frances L. and Schultz, Michael K.},

  abstractNote = {A method for preparation of Pb-212 and Pb-203 labeled chelator-modified peptide-based radiopharmaceuticals for cancer imaging and radionuclide therapy has been developed and adapted for automated clinical production. Pre-concentration and isolation of radioactive Pb2+ from interfering metals in dilute hydrochloric acid was optimized using a commercially-available Pb-specific chromatography resin packed in disposable plastic columns. The pre-concentrated radioactive Pb2+ is eluted in NaOAc buffer directly to the reaction vessel containing chelator-modified peptides. Radiolabeling was found to proceed efficiently at 85 °C (45 min; pH 5.5). The specific activity of radiolabeled conjugates was optimized by separation of radiolabeled conjugates from unlabeled peptide via HPLC. Preservation of bioactivity was confirmed by in vivo biodistribution of Pb-203 and Pb-212 labeled peptides in melanoma-tumor-bearing mice. The approach has been found to be robustly adaptable to automation and a cassette-based fluid-handling system (Modular Lab Pharm Tracer) has been customized for clinical radiopharmaceutical production. Our findings demonstrate that the Pb-203/Pb-212 combination is a promising elementally-matched radionuclide pair for image-guided radionuclide therapy for melanoma, neuroendocrine tumors, and potentially other cancers.},

  doi          = {10.1016/j.apradiso.2017.05.006},

  journal      = {Applied Radiation and Isotopes},

  number       = C,

  volume       = 127,

  place        = {United States},

  year         = {2017},

  month        = {5}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (DOE)

Publisher's Version of Record

DOI: 10.1016/j.apradiso.2017.05.006

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 5 works

Citation information provided by
Web of Science

Figures / Tables:

Fig. 1: ²²⁴Ra/²¹²Pb generator and decay scheme, including parent radionuclide ²²⁸Th. ²¹²Pb is eluted periodically (approximately once every 24 h). The generator has a useful life that is governed by the 3.62 day half life of ²²⁴Ra.

All figures and tables (8 total)

Save / Share:

Export Metadata

Save to My Library

Figures / Tables found in this record:

Figures/Tables have been extracted from DOE-funded journal article accepted manuscripts.

Similar records in OSTI.GOV collections:

Preparation of Radiopharmaceuticals Labeled with Metal Radionuclides

Technical Report Welch, M.J.

The overall goal of this project was to develop methods for the production of metal-based radionuclides, to develop metal-based radiopharmaceuticals and in a limited number of cases, to translate these agents to the clinical situation. Initial work concentrated on the application of the radionuclides of Cu, Cu-60, Cu-61 and Cu-64, as well as application of Ga-68 radiopharmaceuticals. Initially Cu-64 was produced at the Missouri University Research Reactor and experiments carried out at Washington University. A limited number of studies were carried out utilizing Cu-62, a generator produced radionuclide produced by Mallinckrodt Inc. (now Covidien). In these studies, copper-62-labeled pyruvaldehyde Bis(N{supmore »« less
DOI: 10.2172/1034900

Full Text Available
Targeted Therapy for Melanoma

Technical Report Quinn, Thomas ; Moore, Herbert

The research project, entitled ”Targeted Therapy for Melanoma,” was focused on investigating the use of kidney protection measures to lower the non-specific kidney uptake of the radiolabeled Pb-DOTA-ReCCMSH peptide. Previous published work demonstrated that the kidney exhibited the highest non-target tissue uptake of the ^212Pb/203Pb radiolabeled melanoma targeting peptide DOTA-ReCCMSH. The radiolabeled alpha-melanocyte stimulating hormone (α-MSH) peptide analog DOTA-Re(Arg ¹¹)CCMSH, which binds the melanocortin-1 receptor over-expressed on melanoma tumor cells, has shown promise as a PRRT agent in pre-clinical studies. High tumor uptake of ²¹²Pb labeled DOTA-Re(Arg ¹¹)CCMSH resulted in tumor reduction or eradication in melanoma therapy studies. Of particularmore »« less
DOI: 10.2172/1334319

Full Text Available
Melanoma Therapy with Rhenium-Cyclized Alpha Melanocyte Stimulating Hormone Peptide Analogs

Technical Report Thomas P Quinn

Malignant melanoma is the 6th most commonly diagnosed cancer with increasing incidence in the United States. It is estimated that 54,200 cases of malignant melanoma will be newly diagnosed and 7,600 cases of death will occur in the United States in the year 2003 (1). At the present time, more than 1.3% of Americans will develop malignant melanoma during their lifetime (2). The average survival for patients with metastatic melanoma is about 6-9 months (3). Moreover, metastatic melanoma deposits are resistant to conventional chemotherapy and external beam radiation therapy (3). Systematic chemotherapy is the primary therapeutic approach to treat patientsmore »« less
DOI: 10.2172/951315

Full Text Available
Development and Testing of a 212Pb/212Bi Peptide for Targeting Metastatic Melanoma

Technical Report Fisher, Darrell R.

The purpose of this project is to develop a new radiolabeled peptide for imaging and treating metastatic melanoma. The immunoconjugate consists of a receptor-specific peptide that targets melanoma cells. The beta-emitter lead-212 (half-life = 10.4 hours) is linked by coordination chemistry to the peptide. After injection, the peptide targets melanoma receptors on the surfaces of melanoma cells. Lead-212 decays to the alpha-emitter bismuth-212 (half-life = 60 minutes). Alpha-particles that hit melanoma cell nuclei are likely to kill the melanoma cell. For cancer cell imaging, the lead-212 is replaced by lead-203 (half-life = 52 hours). Lead-203 emits 279 keV photons (80.1%more »« less
DOI: 10.2172/1054055

Full Text Available
ASTATINE-211 RADIOCHEMISTRY: THE DEVELOPMENT OF METHODOLOGIES FOR HIGH ACTIVITY LEVEL RADIOSYNTHESIS

Technical Report MICHAEL R. ZALUTSKY

Targeted radionuclide therapy is emerging as a viable approach for cancer treatment because of its potential for delivering curative doses of radiation to malignant cell populations while sparing normal tissues. Alpha particles such as those emitted by 211At are particularly attractive for this purpose because of their short path length in tissue and high energy, making them highly effective in killing cancer cells. The current impact of targeted radiotherapy in the clinical domain remains limited despite the fact that in many cases, potentially useful molecular targets and labeled compounds have already been identified. Unfortunately, putting these concepts into practice hasmore »« less
DOI: 10.2172/1047758

Full Text Available

Similar Records

Title: Automated cassette-based production of high specific activity [ 203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer

Abstract

Citation Formats

Figures / Tables:

Title: Automated cassette-based production of high specific activity [ ^203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer